Part D results
CMS's year-end Part D reconciliation, 2022–2024. When a plan's actual drug costs land well above its bid, CMS shares the loss through risk sharing (the "risk corridors"); when they land well below, the plan pays CMS back. A large positive amount means the plan's drug bid was badly underpriced. 2024 is the latest year CMS has published.
How to read this
Risk sharing: positive = CMS paid the plan (costs ran over the bid by more than the corridor); negative = the plan paid CMS. These are CMS's settled figures. Plans also report risk sharing in their MLR filings, sometimes as an estimate made before CMS settled, so a filing can differ.
Per member per year: risk sharing ÷ Part D member-months × 12. Part D member-months include stand-alone drug plan (PDP) members.
CMS's reconciliation also settles reinsurance (catastrophic drug costs) and low-income cost sharing; those are pass-through subsidies, not a sign of profit or loss, so they're shown on contract pages only.
| 2024 | 2023 | 2022 | 3-year total | Per member per year2024 | Part D members2024 avg | |
|---|---|---|---|---|---|---|
| H5995 ATRIO Health Plans | −$103K | $0 | $5.8K | −$97.4K | −$48 | 2,147 |
| H3814 ATRIO Health Plans | −$200K | −$447K | −$141K | −$788K | −$71 | 2,827 |
| H6743 ATRIO Health Plans | −$1.6M | $232K | $66.2K | −$1.3M | −$72 | 22,402 |
| H7006 ATRIO Health Plans | −$1.5M | $77.0K | $38.4K | −$1.3M | −$156 | 9,331 |
Red = CMS paid the plan. Sorted by the 3-year total. Parent totals add up each contract under its current parent; CMS also publishes its own parent rollup, which can differ where contracts changed hands.